Clinical trial

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

NCT02347072

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention GFF MDI (PT003) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo MDI Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Spiriva® Respimat® (Tiotropium Bromide) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-02-01

PhasePHASE3

Conditions

COPDverified · MONDO: chronic obstructive pulmonary disease

Interventions

GFF MDI (PT003)DRUG

Placebo MDIDRUG

Spiriva® Respimat® (Tiotropium Bromide)DRUG

Sponsors & collaborators

Pearl Therapeutics, Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02347072 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.